Scan to Download ios&Android APP

Trade Otonomy, Inc. - OTIC CFD

0.38
2.56%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading Conditions
Long position overnight fee -0.0225%
Short position overnight fee -0.0219%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 0.39
Open* 0.38
Day's Range* 0.38 - 0.38
1-Year Change* -5%
Volume N/A
Average Vol. (3m) 30.9977
52 wk Range N/A
Market Cap 21.0864
P/E Ratio N/A
Shares Outstanding 56990400
Revenue N/A
EPS -0.78209
Dividend (Yield %) N/A
Beta 1.19603
Next Earnings Date Nov 8, 2022

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Aug 9, 2022 0.38 0.00 0.00% 0.38 0.38 0.38
Aug 3, 2022 0.39 0.00 0.00% 0.39 0.44 0.39
Aug 1, 2022 0.39 -0.01 -2.50% 0.40 0.40 0.39
Jul 29, 2022 1.40 -0.11 -7.28% 1.51 1.52 1.32
Jul 28, 2022 1.49 -0.19 -11.31% 1.68 1.70 1.43
Jul 27, 2022 1.74 -0.04 -2.25% 1.78 1.83 1.66
Jul 26, 2022 1.81 -0.12 -6.22% 1.93 1.93 1.61
Jul 25, 2022 1.92 -0.03 -1.54% 1.95 2.01 1.88
Jul 22, 2022 1.97 0.09 4.79% 1.88 2.02 1.81
Jul 21, 2022 1.91 -0.03 -1.55% 1.94 1.98 1.86
Jul 20, 2022 2.18 0.06 2.83% 2.12 2.26 2.12
Jul 19, 2022 2.20 0.08 3.77% 2.12 2.29 2.10
Jul 18, 2022 2.12 0.04 1.92% 2.08 2.16 2.05
Jul 15, 2022 2.11 0.09 4.46% 2.02 2.11 1.93
Jul 14, 2022 1.96 -0.19 -8.84% 2.15 2.22 1.91
Jul 13, 2022 2.19 0.00 0.00% 2.19 2.25 2.18
Jul 12, 2022 2.20 0.10 4.76% 2.10 2.20 2.10
Jul 11, 2022 2.18 0.09 4.31% 2.09 2.21 2.09
Jul 8, 2022 2.17 0.08 3.83% 2.09 2.21 2.09
Jul 7, 2022 2.15 0.08 3.86% 2.07 2.20 2.06

Otonomy, Inc. Events

Time (UTC) Country Event
Tuesday, November 8, 2022
10:59
  US
Q3 2022 Otonomy Inc Earnings Release
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 0.683 1.236 0.745 0.6 0.273 0.125
Revenue 0.683 1.236 0.745 0.6 0.273 0.125
Cost of Revenue, Total 1.664 3.098 0.934 0.912 0.888 0.37
Gross Profit -0.981 -1.862 -0.189 -0.312 -0.615 -0.245
Total Operating Expense 112.164 92.637 52.798 45.407 43.76 49.75
Selling/General/Admin. Expenses, Total 49.777 46.838 20.008 11.69 14.575 14.707
Research & Development 60.723 42.701 31.856 32.805 27.997 34.673
Operating Income -111.481 -91.401 -52.053 -44.807 -43.487 -49.625
Interest Income (Expense), Net Non-Operating 0.899 1.271 1.685 0.132 -1.244 -1.556
Other, Net -0.001 0 0
Net Income Before Taxes -110.583 -90.13 -50.368 -44.675 -44.731 -51.181
Net Income After Taxes -110.583 -90.13 -50.368 -44.675 -44.731 -51.181
Net Income Before Extra. Items -110.583 -90.13 -50.368 -44.675 -44.731 -51.181
Net Income -110.583 -90.13 -50.368 -44.675 -44.731 -51.181
Total Adjustments to Net Income 0
Income Available to Common Excl. Extra. Items -110.583 -90.13 -50.368 -44.675 -44.731 -51.181
Income Available to Common Incl. Extra. Items -110.583 -90.13 -50.368 -44.675 -44.731 -51.181
Diluted Net Income -110.583 -90.13 -50.368 -44.675 -44.731 -51.181
Diluted Weighted Average Shares 29.9628 30.3042 30.6102 30.7268 40.8458 63.4413
Diluted EPS Excluding Extraordinary Items -3.69068 -2.97418 -1.64546 -1.45394 -1.09512 -0.80675
Diluted Normalized EPS -3.69068 -2.97418 -1.64546 -1.45394 -1.08777 -0.79571
Total Extraordinary Items 0
Unusual Expense (Income) 0.3
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total revenue 0.09 0.035 0 0 0
Revenue 0.09 0.035 0 0 0
Cost of Revenue, Total 0.23 0.14 0 0 0
Gross Profit -0.14 -0.105 0 0 0
Total Operating Expense 11.933 12.166 12.479 13.172 13.154
Selling/General/Admin. Expenses, Total 4.043 3.669 3.501 3.494 3.748
Research & Development 7.66 8.357 8.978 9.678 9.406
Operating Income -11.843 -12.131 -12.479 -13.172 -13.154
Interest Income (Expense), Net Non-Operating -0.367 -0.381 -0.401 -0.407 -0.398
Net Income Before Taxes -12.21 -12.512 -12.88 -13.579 -13.552
Net Income After Taxes -12.21 -12.512 -12.88 -13.579 -13.552
Net Income Before Extra. Items -12.21 -12.512 -12.88 -13.579 -13.552
Net Income -12.21 -12.512 -12.88 -13.579 -13.552
Income Available to Common Excl. Extra. Items -12.21 -12.512 -12.88 -13.579 -13.552
Income Available to Common Incl. Extra. Items -12.21 -12.512 -12.88 -13.579 -13.552
Diluted Net Income -12.21 -12.512 -12.88 -13.579 -13.552
Diluted Weighted Average Shares 52.3191 65.6278 67.7924 67.856 67.8457
Diluted EPS Excluding Extraordinary Items -0.23338 -0.19065 -0.18999 -0.20012 -0.19975
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.23338 -0.19065 -0.18999 -0.20012 -0.19975
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 202.22 122.445 100.069 63.15 88.715 80.468
Cash and Short Term Investments 196.378 120.004 97.284 60.67 86.343 77.412
Cash & Equivalents 24.156 18.456 33.633 25.194 30.767 77.412
Short Term Investments 172.222 101.548 63.651 35.476 55.576 0
Total Receivables, Net 0.091 0.107 0.108 0.048
Accounts Receivable - Trade, Net 0.091 0.107 0.108 0.048
Total Inventory 1.435 0.006 0.227
Prepaid Expenses 2.161 0.729 0.258 0.209 3.056
Other Current Assets, Total 2.155 1.599 2.419 2.223 2.145
Total Assets 208.596 128.364 104.992 83.018 106.265 95.637
Property/Plant/Equipment, Total - Net 4.977 4.679 3.996 19.167 16.848 14.467
Property/Plant/Equipment, Total - Gross 6.817 7.373 7.843 24.014 22.727 20.847
Accumulated Depreciation, Total -1.84 -2.694 -3.847 -4.847 -5.879 -6.38
Other Long Term Assets, Total 1.399 1.24 0.927 0.701 0.702 0.702
Total Current Liabilities 15.233 8.191 7.49 12.498 10.994 12.333
Accounts Payable 1.292 0.961 1.029 1.061 0.749 0.99
Accrued Expenses 13.903 7.188 6.423 11.364 10.227 11.252
Notes Payable/Short Term Debt 0 0 0 0 0 0
Other Current Liabilities, Total 0.038 0.042 0.038 0
Total Liabilities 15.859 11.085 25.255 42.785 39.999 40.73
Total Long Term Debt 0 0 14.764 14.981 15.158 16.205
Other Liabilities, Total 0.626 2.894 3.001 15.306 13.847 12.192
Total Equity 192.737 117.279 79.737 40.233 66.266 54.907
Common Stock 0.03 0.031 0.031 0.031 0.048 0.057
Additional Paid-In Capital 467.468 482.198 494.947 500.084 570.841 610.655
Retained Earnings (Accumulated Deficit) -274.72 -364.85 -415.218 -459.893 -504.624 -555.805
Other Equity, Total -0.041 -0.1 -0.023 0.011 0.001 0
Total Liabilities & Shareholders’ Equity 208.596 128.364 104.992 83.018 106.265 95.637
Total Common Shares Outstanding 30.2553 30.5587 30.6854 30.8142 48.319 56.7325
Redeemable Preferred Stock 0 0 0
Long Term Debt 14.764 14.967 15.158 15.997
Current Port. of LT Debt/Capital Leases 0.073 0.018 0.091
Capital Lease Obligations 0.014 0 0.208
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 76.877 99.352 89.287 80.468 66.378
Cash and Short Term Investments 73.829 97.878 87.096 77.412 62.874
Cash & Equivalents 51.016 85.096 81.843 77.412 62.874
Short Term Investments 22.813 12.782 5.253 0
Total Inventory 0.455
Other Current Assets, Total 2.593
Total Assets 93.406 115.419 104.878 95.637 81.232
Property/Plant/Equipment, Total - Net 15.605 15.153 14.677 14.467 14.152
Property/Plant/Equipment, Total - Gross 21.705 21.172 20.908 20.847 20.72
Accumulated Depreciation, Total -6.1 -6.019 -6.231 -6.38 -6.568
Other Long Term Assets, Total 0.924 0.914 0.914 0.702 0.702
Total Current Liabilities 10.696 8.83 9.742 12.333 10.038
Accounts Payable 0.473 1.259 0.467 0.99 1.347
Accrued Expenses 8.266 7.571 9.275 11.252 8.6
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 1.957 0.091 0.091
Total Liabilities 37.382 37.766 38.34 40.73 37.983
Total Long Term Debt 13.246 15.913 15.955 16.205 16.232
Long Term Debt 13.246 15.913 15.955 15.997 16.04
Other Liabilities, Total 13.44 13.023 12.643 12.192 11.713
Total Equity 56.024 77.653 66.538 54.907 43.249
Redeemable Preferred Stock 0 0
Common Stock 0.048 0.057 0.057 0.057 0.057
Additional Paid-In Capital 572.805 606.941 608.707 610.655 612.549
Retained Earnings (Accumulated Deficit) -516.834 -529.346 -542.226 -555.805 -569.357
Other Equity, Total 0.005 0.001 0 0
Total Liabilities & Shareholders’ Equity 93.406 115.419 104.878 95.637 81.232
Total Common Shares Outstanding 48.3192 56.6813 56.6813 56.7325 56.9216
Prepaid Expenses 1.474 2.191 3.056 3.504
Capital Lease Obligations 0.208 0.192
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line -110.583 -90.13 -50.368 -44.675 -44.731 -51.181
Cash From Operating Activities -94.305 -75.307 -38.434 -36.925 -38.874 -42.418
Cash From Operating Activities 0.708 1.289 1.186 1.149 1.062 0.856
Non-Cash Items 14.655 18.237 12.011 4.292 6.273 8.381
Changes in Working Capital 0.915 -4.703 -1.263 2.309 -1.478 -0.474
Cash From Investing Activities -149.417 68.998 37.984 28.296 -20.215 55.963
Capital Expenditures -2.546 -1.259 -0.496 -0.7 -0.134 -0.295
Other Investing Cash Flow Items, Total -146.871 70.257 38.48 28.996 -20.081 56.258
Cash From Financing Activities 109.216 1.07 15.165 0.195 64.663 33.1
Issuance (Retirement) of Stock, Net 109.216 1.07 0.335 0.247 64.663 32.426
Issuance (Retirement) of Debt, Net 0 14.83 0 0 0.674
Net Change in Cash -134.506 -5.239 14.715 -8.434 5.574 46.645
Cash Interest Paid 1.394 1.373 1.422
Financing Cash Flow Items -0.052 0 0
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -12.21 -24.722 -37.602 -51.181 -13.552
Cash From Operating Activities -12.367 -21.95 -32.65 -42.418 -14.344
Cash From Operating Activities 0.221 0.436 0.648 0.856 0.195
Non-Cash Items 2.757 4.638 6.474 8.381 1.937
Cash Interest Paid 0.338 0.686 1.054 1.422 0.36
Changes in Working Capital -3.135 -2.302 -2.17 -0.474 -2.924
Cash From Investing Activities 32.615 43.27 50.717 55.963 -0.194
Capital Expenditures -0.13 -0.243 -0.296 -0.295 -0.194
Other Investing Cash Flow Items, Total 32.745 43.513 51.013 56.258 0
Cash From Financing Activities 0.001 33.009 33.009 33.1 0
Issuance (Retirement) of Stock, Net 0.001 32.335 32.335 32.426 0
Net Change in Cash 20.249 54.329 51.076 46.645 -14.538
Issuance (Retirement) of Debt, Net 0.674 0.674 0.674
Financing Cash Flow Items 0

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
427000+

Traders

71000+

Active clients monthly

$46000000+

Monthly investing volume

$17000000+

Withdrawn each month

Otonomy, Inc. Company profile

About Otonomy Inc

Otonomy, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics for neurotology. The Company pipeline includes OTIPRIO, OTIVIDEX, OTO-313, and OTO-413. OTIPRIO is a single-dose, physician-administered antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery for the treatment of patients with acute otitis externa (AOE). OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Menieres disease. OTO-313 is a sustained-exposure formulation of gacyclidine, a potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist, in in Phase II for tinnitus. OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) in Phase IIa development for the repair of cochlear synaptopathy, an underlying pathology in age-related and noise-induced hearing loss. OTO-825, a gene therapy for congenital hearing loss.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Otonomy Inc revenues decreased 54% to $125K. Net loss increased 14% to $51.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 23% to $31.3M (expense), Stock-based Com increase of 37% to $3.4M (expense).

Industry: Bio Therapeutic Drugs

5626 Oberlin Drive, Suite 100
SAN DIEGO
CALIFORNIA 92121
US

Income statement

People Also Watch

US Tech 100 (Nasdaq)

13,566.40 Price
+1.750% 1D Chg, %
Long position overnight fee -0.0116%
Short position overnight fee 0.0025%
Overnight fee time 21:00 (UTC)
Spread 1.5

Still looking for a broker you can trust?

Join the 427.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading